These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 2493331)

  • 1. Cost-effectiveness of primary tetanus vaccination among elderly Canadians.
    Muckle TJ
    CMAJ; 1989 Mar; 140(6):586-7. PubMed ID: 2493331
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of primary tetanus vaccination among elderly Canadians.
    Hutchison BG; Stoddart GL
    CMAJ; 1988 Dec; 139(12):1143-51. PubMed ID: 3143478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [[Health and economic benefits of mandatory regular vaccination in the Slovak Republic. III. Diphtheria, tetanus and pertussis] ].
    Hudecková H; Straka S; Szilágyiová M; Rusnáková S
    Epidemiol Mikrobiol Imunol; 2000 Nov; 49(4):153-7. PubMed ID: 11188762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Economic evaluation of an extraordinary vaccination against tetanus in CSR (author's transl)].
    Janout V; Walter G; Svandová E; Král L
    Cesk Epidemiol Mikrobiol Imunol; 1982 Jan; 31(1):9-14. PubMed ID: 6460567
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.
    Postma MJ; Heijnen ML; Beutels P; Jager JC
    Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Function of tetanus immunoglobulin in case of injury: administration often unnecessary].
    de Melker HE; Steyerberg EW
    Ned Tijdschr Geneeskd; 2004 Feb; 148(9):429-33. PubMed ID: 15038204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental cost-effectiveness of supplementary immunization activities to prevent neonatal tetanus in Pakistan.
    Griffiths UK; Wolfson LJ; Quddus A; Younus M; Hafiz RA
    Bull World Health Organ; 2004 Sep; 82(9):643-51. PubMed ID: 15628201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical prevalence of antibodies minimizing vaccination costs for hepatitis A, hepatitis B, varicella, measles and tetanus in adults and adolescents in Catalonia, Spain.
    Plans-Rubió P
    Vaccine; 2004 Sep; 22(29-30):4002-13. PubMed ID: 15364450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries.
    Ament A; Baltussen R; Duru G; Rigaud-Bully C; de Graeve D; Ortqvist A; Jönsson B; Verhaegen J; Gaillat J; Christie P; Cifre AS; Vivas D; Loiseau C; Fedson DS
    Clin Infect Dis; 2000 Aug; 31(2):444-50. PubMed ID: 10987703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Primary care: vaccination. An example of convincing economic savings].
    Gattorno Ruiz R; Barbón Ruiz D; Olivera Martínez A
    Rev Cubana Enferm; 1986; 2(3):233-41. PubMed ID: 3649846
    [No Abstract]   [Full Text] [Related]  

  • 11. Policy evaluation for the subsidy for influenza vaccination in elderly.
    Ohkusa Y
    Vaccine; 2005 Mar; 23(17-18):2256-60. PubMed ID: 15755606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis].
    Postma MJ; Heijnen ML; Beutels P; Jager JC
    Ned Tijdschr Geneeskd; 2002 May; 146(18):855-9. PubMed ID: 12038224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of clinical outcome and outcome period definitions on estimates of absolute clinical and economic benefits of influenza vaccination in community dwelling elderly persons.
    Nichol KL; Nordin J; Mullooly J
    Vaccine; 2006 Mar; 24(10):1562-8. PubMed ID: 16300868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and effectiveness of influenza vaccination among Thai elderly persons living in the community.
    Praditsuwan R; Assantachai P; Wasi C; Puthavatana P; Kositanont U
    J Med Assoc Thai; 2005 Feb; 88(2):256-64. PubMed ID: 15962680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-benefit analysis of hepatitis B vaccination.
    Jönsson B
    Postgrad Med J; 1987; 63 Suppl 2():27-32. PubMed ID: 3120169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary high-dose intradermal hepatitis B vaccination in hemodialysis: cost-effectiveness evaluation at 2 years.
    Mat O; Mestrez F; Beauwens R; Muniz-Martinez MC; Dhaene M
    Hemodial Int; 2006 Jan; 10(1):49-55. PubMed ID: 16441827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost-effectiveness analysis of hepatitis B vaccination in People's Liberation Army].
    Hu R; Cao W; Zhang X
    Zhonghua Liu Xing Bing Xue Za Zhi; 2001 Apr; 22(2):142-5. PubMed ID: 11860866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antitetanus prophylaxis: actual practice and cost benefit analysis of a hypothetical mass vaccination].
    Palombino R; Greco M; Morra G; Pitzurra M
    Boll Ist Sieroter Milan; 1987; 66(5):402-10. PubMed ID: 3449103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effectiveness of influenza vaccination The Netherlands].
    Reinders A; Postma MJ; Govaert TM; Sprenger MJ
    Ned Tijdschr Geneeskd; 1997 Jan; 141(2):93-7. PubMed ID: 9036354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federation.
    Platonov AE; Griffiths UK; Voeykova MV; Platonova OV; Shakhanina IL; Chistyakova GG; Robertson SE;
    Vaccine; 2006 Mar; 24(13):2367-76. PubMed ID: 16413949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.